These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 16028167

  • 1. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
    Brooks JT, Song R, Hanson DL, Wolfe M, Swerdlow DL, Adult and Adolescent Spectrum of Disease Working Group.
    Clin Infect Dis; 2005 Aug 15; 41(4):549-53. PubMed ID: 16028167
    [Abstract] [Full Text] [Related]

  • 2. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy.
    Powderly WG.
    Clin Infect Dis; 2000 Aug 15; 31(2):597-601. PubMed ID: 10987727
    [Abstract] [Full Text] [Related]

  • 3. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, Jouan M, Bricaire F, Katlama C.
    Clin Infect Dis; 2002 Mar 01; 34(5):662-7. PubMed ID: 11810599
    [Abstract] [Full Text] [Related]

  • 4. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P, Chan K, Hogg R, Bessuille E, Black W, Talbot J, O'Shaughnessy M, Montaner J.
    Clin Infect Dis; 2002 Feb 01; 34(3):371-8. PubMed ID: 11774085
    [Abstract] [Full Text] [Related]

  • 5. [Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment].
    Schneider MM, Reiss P, Borleffs JC, Rozenberg-Arska M, Hoepelman IM.
    Ned Tijdschr Geneeskd; 1997 Jan 11; 141(2):80-3. PubMed ID: 9036351
    [Abstract] [Full Text] [Related]

  • 6. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 cell count following highly active antiretroviral therapy.
    Gill J, Moyle G, Nelson M.
    AIDS; 1998 Apr 16; 12(6):680. PubMed ID: 9583614
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
    Jung Y, Song KH, Choe PG, Park WB, Bang JH, Kim ES, Kim HB, Park SW, Kim NJ, Oh MD.
    Int J STD AIDS; 2017 Dec 16; 28(14):1426-1432. PubMed ID: 28592210
    [Abstract] [Full Text] [Related]

  • 9. Update: prophylaxis for HIV opportunistic infections.
    Murphy MJ.
    Fac Notes (New Orleans La); 1998 Dec 16; 10(1):5-6. PubMed ID: 11365025
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mycobacterium avium complex infection in HIV/AIDS patients.
    Corti M, Palmero D.
    Expert Rev Anti Infect Ther; 2008 Jun 16; 6(3):351-63. PubMed ID: 18588499
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
    Lange CG, Woolley IJ, Brodt RH.
    Drugs; 2004 Jun 16; 64(7):679-92. PubMed ID: 15025543
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
    Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, Lennox JL, Dube MP, MacGregor RR, Currier JS, AIDS Clinical Trial Group 393 Study Team.
    J Infect Dis; 2003 Apr 01; 187(7):1046-52. PubMed ID: 12660918
    [Abstract] [Full Text] [Related]

  • 16. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, Ward J.
    MMWR CDC Surveill Summ; 1999 Apr 16; 48(2):1-22. PubMed ID: 12412613
    [Abstract] [Full Text] [Related]

  • 17. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
    Yangco BG, Buchacz K, Baker R, Palella FJ, Armon C, Brooks JT, HIV Outpatient Study Investigators.
    AIDS Patient Care STDS; 2014 Jun 16; 28(6):280-3. PubMed ID: 24833016
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease.
    Sterling TR, Moore RD, Graham NM, Astemborski J, Vlahov D, Chaisson RE.
    AIDS; 1998 Aug 20; 12(12):1451-7. PubMed ID: 9727565
    [Abstract] [Full Text] [Related]

  • 20. OI prophylaxis in antiretroviral responders: stay the course or bite the bullet?
    Currier JS.
    AIDS Clin Care; 1998 Oct 20; 10(10):73-5, 79-80. PubMed ID: 11365859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.